Diet changes before surgery for hormone-receptor breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether changing your diet before your breast surgery can help people with early, hormone-receptor (ER/PR+) breast cancer. It focuses on patients who have not started treatment yet and want to keep surgery as the main treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 80
- Your breast cancer is early (stage I to III), not metastatic, and is ER and/or PR positive and HER2 negative
- You have not started any treatment for this current breast cancer yet, and surgery is planned first
- Your body weight is in a specific range based on BMI (with slightly different limits if you are age 70+)
- You can follow the study and give written consent, and you must have acceptable recent blood test, heart test (ECG/QTc), and general health (performance status 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a ketogenic diet (high fat, low carb) can help change the environment around breast cancer tumors in ways that might slow cancer growth. You'll follow the diet for several months while researchers monitor your health and take measurements.
This trial tests whether eating specially prepared healthy meals for a few weeks before surgery can help improve recovery and overall health in women with early-stage breast cancer. Participants will receive all their meals from the study during this time.
This study tests if a special diet that mimics fasting can help reduce side effects from hormone therapy (aromatase inhibitors) in women with breast cancer. The diet is a low-calorie meal plan designed to lower cholesterol and improve well-being.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This trial tests a new drug (SHR-A1811) alone or with letrozole given before surgery to shrink early-stage breast cancer that is hormone receptor-positive and HER2-low. It may help make surgery more effective.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.